Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2015 Dec 10

PMID 26647423

Citations 95

Authors

Kirti Bhatt

Linda L Lanting

Ye Jia

Sailee Yadav

Marpadga A Reddy

Nathaniel Magilnick

Mark Boldin

Rama Natarajan

Affiliations

Soon will be listed here.

Abstract

Inflammation has a critical role in the pathogenesis of diabetic complications, including diabetic nephropathy (DN). MicroRNAs have recently emerged as important regulators of DN. However, the role of microRNAs in the regulation of inflammation during DN is poorly understood. Here, we examined the in vivo role of microRNA-146a (miR-146a), a known anti-inflammatory microRNA, in the pathogenesis of DN. In a model of streptozotocin-induced diabetes, miR-146a(-/-) mice showed significantly exacerbated proteinuria, renal macrophage infiltration, glomerular hypertrophy, and fibrosis relative to the respective levels in control wild-type mice. Diabetes-induced upregulation of proinflammatory and profibrotic genes was significantly greater in the kidneys of miR-146a(-/-) than in the kidneys of wild-type mice. Notably, miR-146a expression increased in both peritoneal and intrarenal macrophages in diabetic wild-type mice. Mechanistically, miR-146a deficiency during diabetes led to increased expression of M1 activation markers and suppression of M2 markers in macrophages. Concomitant with increased expression of proinflammatory cytokines, such as IL-1β and IL-18, markers of inflammasome activation also increased in the macrophages of diabetic miR-146a(-/-) mice. These studies suggest that in early DN, miR-146a upregulation exerts a protective effect by downregulating target inflammation-related genes, resulting in suppression of proinflammatory and inflammasome gene activation. Loss of this protective mechanism in miR-146a(-/-) mice leads to accelerated DN. Taken together, these results identify miR-146a as a novel anti-inflammatory noncoding RNA modulator of DN.

Citing Articles

The Impact of Epigenetics on the Pathophysiology of Type 2 Diabetes and Associated Nephropathic Complications.

Mukherjee A, Debbarman T, Banerjee B, Siddiqi S Indian J Endocrinol Metab. 2025; 28(6):569-578.

PMID: 39881775 PMC: 11774419. DOI: 10.4103/ijem.ijem_43_24.

Bioinformatics analysis of miRNAs germacrone protection on diabetic nephropathy.

Wang B, He W, Xie Z, Zhang J, Ren Y, He Q Sci Rep. 2024; 14(1):31754.

PMID: 39738220 PMC: 11685625. DOI: 10.1038/s41598-024-81944-4.

MiRNA Expression in Long-Distance Runners with Musculoskeletal Pain: Implications for Pain Pathophysiology.

Tumolo M, Bodini A, Bagordo F, Leo C, Mincarone P, De Matteis E Biomedicines. 2024; 12(11).

PMID: 39595060 PMC: 11591860. DOI: 10.3390/biomedicines12112494.

Extracellular Vesicles Derived from Human Liver Stem Cells Counteract Chronic Kidney Disease Development and Cardiac Dysfunction in Remnant Kidney Murine Model: The Possible Involvement of Proteases.

Ceccotti E, Chiabotto G, Cedrino M, Gambella A, Delsedime L, Ghigo A Biomedicines. 2024; 12(7).

PMID: 39062090 PMC: 11274379. DOI: 10.3390/biomedicines12071517.

Role of miRNAs in macrophage-mediated kidney injury.

Li J, Yan X, Wu Z, Shen J, Li Y, Zhao Y Pediatr Nephrol. 2024; 39(12):3397-3410.

PMID: 38801452 DOI: 10.1007/s00467-024-06414-5.

References

Wendt T, Tanji N, Guo J, Hudson B, Bierhaus A, Ramasamy R . Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003; 14(5):1383-95. DOI: 10.1097/01.asn.0000065100.17349.ca. View

Liang G, Zhu Y, Sun B, Shao Y, Jing A, Wang J . Assessing the survival of exogenous plant microRNA in mice. Food Sci Nutr. 2014; 2(4):380-8. PMC: 4221836. DOI: 10.1002/fsn3.113. View

Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H . Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem. 2011; 351(1-2):197-205. DOI: 10.1007/s11010-011-0727-3. View

Chen N, Chong T, Loh H, Lim K, Gan V, Wang M . Negative regulatory responses to metabolically triggered inflammation impair renal epithelial immunity in diabetes mellitus. J Mol Med (Berl). 2012; 91(5):587-98. PMC: 3644409. DOI: 10.1007/s00109-012-0969-x. View

McClelland A, Hagiwara S, Kantharidis P . Where are we in diabetic nephropathy: microRNAs and biomarkers?. Curr Opin Nephrol Hypertens. 2013; 23(1):80-6. DOI: 10.1097/01.mnh.0000437612.50040.ae. View

Adler S, Nast C, Artishevsky A . Diabetic nephropathy: pathogenesis and treatment. Annu Rev Med. 1993; 44:303-15. DOI: 10.1146/annurev.me.44.020193.001511. View

Reddy M, Sumanth P, Lanting L, Yuan H, Wang M, Mar D . Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int. 2013; 85(2):362-73. PMC: 3946617. DOI: 10.1038/ki.2013.387. View

Trionfini P, Benigni A, Remuzzi G . MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2014; 11(1):23-33. DOI: 10.1038/nrneph.2014.202. View

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

10.

Lamkanfi M, Dixit V . Mechanisms and functions of inflammasomes. Cell. 2014; 157(5):1013-22. DOI: 10.1016/j.cell.2014.04.007. View

11.

Reddy M, Chen Z, Park J, Wang M, Lanting L, Zhang Q . Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes. 2014; 63(12):4249-61. PMC: 4238007. DOI: 10.2337/db14-0298. View

12.

Sayed D, Abdellatif M . MicroRNAs in development and disease. Physiol Rev. 2011; 91(3):827-87. DOI: 10.1152/physrev.00006.2010. View

13.

Li R, Chung A, Yu X, Lan H . MicroRNAs in Diabetic Kidney Disease. Int J Endocrinol. 2014; 2014:593956. PMC: 3914440. DOI: 10.1155/2014/593956. View

14.

Mathieson P . The podocyte as a target for therapies--new and old. Nat Rev Nephrol. 2011; 8(1):52-6. DOI: 10.1038/nrneph.2011.171. View

15.

Kato M, Natarajan R . Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol. 2014; 10(9):517-30. PMC: 6089507. DOI: 10.1038/nrneph.2014.116. View

16.

Xu J, Wu W, Zhang L, Dorset-Martin W, Morris M, Mitchell M . The role of microRNA-146a in the pathogenesis of the diabetic wound-healing impairment: correction with mesenchymal stem cell treatment. Diabetes. 2012; 61(11):2906-12. PMC: 3478555. DOI: 10.2337/db12-0145. View

17.

Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q . miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes. 2011; 60(11):2975-84. PMC: 3198068. DOI: 10.2337/db11-0478. View

18.

Silahtaroglu A, Nolting D, Dyrskjot L, Berezikov E, Moller M, Tommerup N . Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc. 2007; 2(10):2520-8. DOI: 10.1038/nprot.2007.313. View

19.

Williams M, Nadler J . Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 2007; 7(3):242-8. DOI: 10.1007/s11892-007-0038-y. View

20.

Chandrasekaran K, Karolina D, Sepramaniam S, Armugam A, Wintour E, Bertram J . Role of microRNAs in kidney homeostasis and disease. Kidney Int. 2012; 81(7):617-27. DOI: 10.1038/ki.2011.448. View